

bsm-41117M**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

PD-1 Mouse mAb**— DATASHEET —**

Host: Mouse	Isotype: IgG1	Applications: IHC-P (1:50-200) IHC-F (1:50-200) IF (1:50-200) Reactivity: Human Predicted MW.: 32 kDa Subcellular Location: Cell membrane
Clonality: Monoclonal	CloneNo.: 1C4	
GeneID: 5133	SWISS: Q15116	
Target: PD-1		
Purification: affinity purified by Protein G		
Concentration: 1mg/1ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor expressed in activated T cells; it is involved in the regulation of T-cell functions, including those of effector CD8+ T cells. In addition, this protein can also promote the differentiation of CD4+ T cells into T regulatory cells. PDCD1 is expressed in many types of tumors including melanomas, and has demonstrated to play a role in anti-tumor immunity. Moreover, this protein has been shown to be involved in safeguarding against autoimmunity, however, it can also contribute to the inhibition of effective anti-tumor and anti-microbial immunity. [provided by RefSeq, Aug 2020]		

— VALIDATION IMAGES —

Paraformaldehyde-fixed, paraffin embedded Human Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with PD-1 Monoclonal Antibody, Unconjugated(bsm-41117M) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Mouse, sp-0024) and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with PD-1 Monoclonal Antibody, Unconjugated(bsm-41117M) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Mouse, sp-0024) and DAB (C-0010) staining.

— SELECTED CITATIONS —

- **[IF=5.6]** Meiyang Song. et al. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma. INT IMMUNOPHARMACOL. 2024 Mar;129:111601 IHC ;Mouse. 38350354
- **[IF=6.3]** Qiao-xin Lin. et al.Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer.neoplasia.2025 Jan;59:101077. IHC ;Mouse. 39561585
- **[IF=2.5]** Wang Qi. et al. Correlation between PD-1/PD-L1 and RANKL/OPG in chronic apical periodontitis model of Sprague-Dawley rats. ODONTOLOGY. 2024 Mar;;1-10 IHC ;Rat. 38528238